BioTech: A Prescription for Progression - Market Research on Biomoda, Inc. and Harbor BioSciences, Inc.

   Today, www.GlobalEquityReporter.com announced its research report highlighting Biomoda, Inc. (OTCBB: BMOD) and Harbor BioSciences, Inc. (OTCBB: HRBR). Full report download is available at www.GlobalEquityReporter.com/access.php.

While it is thought that the recent healthcare reform legislation will negatively affect industry profitability over the next few years, new innovations within the healthcare field have maintained an influx of new interest to the industry. Combining medical technology with human touch, the healthcare industry diagnoses, treats, and administers care around the clock -- responding to the needs of millions of people. Pharmaceuticals should remain one of the widest-margin industries, with prospects enhanced by demographic growth in the elderly and new drugs stemming from discoveries in genomics and biotechnology. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.

Global Equity is reporting on Biomoda, Inc. as a development-stage company. It is an invitro diagnostics company, which develops, assays, or tests, to detect cancer. The assays are performed in clinical reference laboratories using body-fluid samples. The technology is based on a porphyrin molecule that has an affinity to bind with cancer cells and cause them to fluoresce red under ultraviolet light. The porphyrin molecule is easy to obtain, manufacture and use. The full report and profile Biomoda, Inc. (OTCBB: BMOD) is available here: www.GlobalEquityReporter.com/get.PDF.1824.php.

Global Equity Reporter brings Harbor BioSciences, Inc. to light as a clinical-stage pharmaceutical company, engaged in the discovery and development of products for the treatment of diseases related to aging. The Company is primarily focused on the development of a series of steroid hormone analogs that are derived from the human adrenal metabolome. The full report and profile on Harbor BioSciences, Inc. (OTCBB: HRBR) is available here: www.GlobalEquityReporter.com/get.PDF.1937.php.

About Global Equity Reporter Global Equity Reporter is a premier source for microcap research -- providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers.

Contact: Alexander Griffin Email Contact www.GlobalEquityReporter.com